<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">OTO</journal-id>
<journal-id journal-id-type="hwp">spoto</journal-id>
<journal-title>Otolaryngology–Head and Neck Surgery</journal-title>
<issn pub-type="ppub">0194-5998</issn>
<issn pub-type="epub">1097-6817</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0194599811421124</article-id>
<article-id pub-id-type="publisher-id">10.1177_0194599811421124</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Case Reports</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Nasal Tetracaine Spray–Induced Methemoglobinemia</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Whited</surname><given-names>Chad</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0194599811421124">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Cohen</surname><given-names>Seth M.</given-names></name>
<degrees>MD, MPH</degrees>
<xref ref-type="aff" rid="aff1-0194599811421124">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-0194599811421124"><label>1</label>Division of Otolaryngology–Head &amp; Neck Surgery, Department of Surgery, Duke University Hospital, Durham, North Carolina, USA</aff>
<author-notes>
<corresp id="corresp1-0194599811421124">Chad Whited, MD, Division of Otolaryngology–Head &amp; Neck Surgery, Department of Surgery, Duke University Hospital, DUMC 3704, Durham, NC 27710, USA Email: <email>chad.whited@duke.edu</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>4</month>
<year>2012</year>
</pub-date>
<volume>146</volume>
<issue>4</issue>
<fpage>678</fpage>
<lpage>679</lpage>
<history>
<date date-type="received">
<day>5</day>
<month>7</month>
<year>2011</year>
</date>
<date date-type="accepted">
<day>2</day>
<month>8</month>
<year>2011</year>
</date>
</history>
<permissions>
<copyright-statement>© American Academy of Otolaryngology—Head and Neck Surgery Foundation 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">Official journal of the American Academy of Otolaryngology–Head and Neck Surgery Foundation</copyright-holder>
</permissions>
<kwd-group>
<kwd>methemoglobinemia</kwd>
<kwd>tetracaine</kwd>
<kwd>nasal spray</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>The use of nasal spray local anesthetics is ubiquitous in otolaryngology for improving comfort during clinical procedures. Tetracaine (Pontocaine) is a local anesthetic of the ester group that is used for spinal and ophthalmologic anesthesia in addition to rhinolaryngologic anesthesia.</p>
<p>Normal hemoglobin contains the reduced ferrous form of iron (Fe<sup>++</sup>), whereas methemoglobin contains the oxidized ferric form (Fe<sup>+++</sup>). Methemoglobinemia is a life-threatening condition in which methemoglobin composes greater than 1% to 2% of red blood cells.</p>
<p>Numerous studies have documented methemoglobinemia from benzocaine and other topical anesthetics; however, we present the first documented report of methemoglobinemia resulting from tetracaine nasal spray.<sup><xref ref-type="bibr" rid="bibr1-0194599811421124">1</xref></sup> The Duke University institutional review board granted exempt status.</p>
<sec id="section1-0194599811421124" sec-type="cases">
<title>Case</title>
<p>A 71-year-old woman presented to the laryngology clinic for evaluation of hoarseness and dysphagia prior to a thyroid lobectomy. Her past medical history was pertinent for a tracheotomy (decannulated), coronary artery disease, and a chronic urinary tract infection for which she was taking sulfamethoxazole-trimethoprim (Bactrim) 100 mg daily. Her vital signs were measured, and each nasal cavity received 1 spray of our hospital-based compound of oxymetazoline hydrochloride 0.025% and tetracaine hydrochloride 1.0%. The patient’s respiratory rate was 16 breaths per minute, and pulse oximetry was 100% on room air. Physical exam was normal except for tethering of her tracheostomy scar. Transnasal fiber-optic laryngoscopy (TFL) revealed a patent airway with no abnormalities and mobile true vocal folds. She tolerated the exam well and was directed to her subsequent anesthesia preoperative appointment. At her preoperative appointment, the patient’s vital signs were rechecked and pulse oximetry was recorded in the low 80s. She was not complaining of dyspnea or chest pain and was immediately transferred to the emergency department (ED). In the ED, she was asymptomatic, with pulse oximetry of 91% on 2 liters nasal cannula and otherwise normal vital signs. An arterial shock panel revealed a hematocrit of 0.35 and methemoglobin level of 10.5%. Toxicology was consulted and did not recommend treatment with methylene blue as the methemoglobin level was less than 20% and the patient was asymptomatic. She was weaned to room air, remained asymptomatic, and was subsequently discharged home from the ED with cephalexin instead of Bactrim and primary care follow-up.</p>
</sec>
<sec id="section2-0194599811421124" sec-type="discussion">
<title>Discussion</title>
<p>This case illustrates a rare but potentially serious complication encountered in the otorhinolaryngology clinic. Normal hemoglobin contains iron in the reduced ferrous state (Fe<sup>++</sup>), whereas methemoglobin contains iron in the oxidized ferric state (Fe<sup>+++</sup>). There is a physiologic level of methemoglobin (&lt;1.5%) that is reduced to hemoglobin by cytochrome b5. Methemoglobin prevents the binding of oxygen and also shifts the oxygen dissociation curve to the left, causing the remaining hemoglobin to bind oxygen tighter, reducing delivery to tissues. Acquired forms of methemoglobinemia are more common than the congenital forms. Etiologies of methemoglobinemia are listed in <xref ref-type="table" rid="table1-0194599811421124"><bold>Table 1</bold></xref>. Signs and symptoms of methemoglobinemia are presented in <xref ref-type="table" rid="table2-0194599811421124"><bold>Table 2</bold></xref>. Treatment for methemoglobinemia ranges from oxygen and observation to methylene blue (1-2 mg/kg by slow intravenous push during 5-10 minutes) to transfusion.<sup><xref ref-type="bibr" rid="bibr2-0194599811421124">2</xref></sup></p>
<table-wrap id="table1-0194599811421124" position="float">
<label>Table 1.</label>
<caption><p>Etiologies of Methemoglobinemia</p></caption>
<graphic alternate-form-of="table1-0194599811421124" xlink:href="10.1177_0194599811421124-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
</colgroup>
<tbody>
<tr>
<td>Hereditary
<list id="list1-0194599811421124" list-type="bullet">
<list-item><p>NADH reductase deficiency</p></list-item>
<list-item><p>Hemoglobin M</p></list-item>
</list></td>
<td rowspan="3">Medications
<list id="list1-0194599811421124" list-type="bullet">
<list-item><p>Benzocaine</p></list-item>
<list-item><p>Chloroquin</p></list-item>
<list-item><p>Dapsone</p></list-item>
<list-item><p>Lidocaine</p></list-item>
<list-item><p>Methylene blue</p></list-item>
<list-item><p>Metoclopramide</p></list-item>
<list-item><p>Nitrites</p></list-item>
<list-item><p>Nitroglycerine</p></list-item>
<list-item><p>Nitroprusside</p></list-item>
<list-item><p>Phenacetin</p></list-item>
<list-item><p>Phenazopyridine</p></list-item>
<list-item><p>Phenytoin</p></list-item>
<list-item><p>Prilocaine</p></list-item>
<list-item><p>Primaquin</p></list-item>
<list-item><p>Pyridium</p></list-item>
<list-item><p>Quinines</p></list-item>
<list-item><p>Rifampin</p></list-item>
<list-item><p>Sulfonamides</p></list-item>
<list-item><p>Trimethoprim</p></list-item>
</list></td>
</tr>
<tr>
<td>Chemical
<list id="list1-0194599811421124" list-type="bullet">
<list-item><p>Aniline dyes</p></list-item>
<list-item><p>Chlorobenzene</p></list-item>
<list-item><p>Indigo carmine</p></list-item>
<list-item><p>Fungicides</p></list-item>
<list-item><p>Herbicides</p></list-item>
<list-item><p>Naphthalene</p></list-item>
<list-item><p>Trinitrotoluene (TNT)</p></list-item>
</list></td>
</tr>
<tr>
<td>Natural
<list id="list1-0194599811421124" list-type="bullet">
<list-item><p>Contaminated well water</p></list-item>
<list-item><p>Fires and smoke inhalation</p></list-item>
</list></td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="table2-0194599811421124" position="float">
<label>Table 2.</label>
<caption><p>Signs and Symptoms of Methemoglobinemia</p></caption>
<graphic alternate-form-of="table2-0194599811421124" xlink:href="10.1177_0194599811421124-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="center"/>
</colgroup>
<thead>
<tr>
<th align="left">Methemoglobin Level</th>
<th align="center">Signs and Symptoms</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;1%</td>
<td>Normal physiologic level</td>
</tr>
<tr>
<td>10%-20%</td>
<td>Cyanosis, chocolate-brown arterial blood</td>
</tr>
<tr>
<td>20%-30%</td>
<td>Tachycardia, headache, anxiety, nausea, dyspnea</td>
</tr>
<tr>
<td>30%-50%</td>
<td>Weakness, fatigue, confusion, dizziness</td>
</tr>
<tr>
<td>50%-70%</td>
<td>Stupor, dizziness, coma, seizure, arrhythmias</td>
</tr>
<tr>
<td>&gt;70%</td>
<td>Death</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>There are conflicting reports as to the efficacy and benefits of using topical anesthetic spray for TFL; however, its use is ubiquitous in an effort to make clinical procedures as comfortable as possible.<sup><xref ref-type="bibr" rid="bibr3-0194599811421124">3</xref>,<xref ref-type="bibr" rid="bibr4-0194599811421124">4</xref></sup> Tetracaine is an ester-type local anesthetic preventing the initiation and transmission of nerve impulses. Compared to other local anesthetics, tetracaine’s anesthetic effects are as good as or better than lidocaine or cocaine. Its onset is slightly slower with a longer duration, making it well suited for longer office procedures while avoiding the need for reapplication.<sup><xref ref-type="bibr" rid="bibr4-0194599811421124">4</xref></sup></p>
<p>Methemoglobinemia is a well-documented side effect of topical anesthetics, especially those containing benzocaine. This led to benzocaine’s prohibition in many hospitals, including the Veterans Affairs.<sup><xref ref-type="bibr" rid="bibr2-0194599811421124">2</xref></sup> All previous methemoglobinemia reports of tetracaine spray involved a cetacaine mixture, in which benzocaine is the most active ingredient.<sup><xref ref-type="bibr" rid="bibr1-0194599811421124">1</xref></sup> There is a single report of methemoglobinemia resulting from tetracaine lozenges requiring methylene blue and blood transfusion but no reports induced by tetracaine spray.<sup><xref ref-type="bibr" rid="bibr5-0194599811421124">5</xref></sup></p>
<p>This patient was taking an oxidizing agent, sulfamethoxazole, which likely combined with tetracaine to cause her methemoglobinemia. Had she not had an immediate subsequent appointment, methemoglobinemia may have never been diagnosed. We recommend that otorhinolaryngologists be mindful of this complication and use caution with an anesthetic spray in patients taking agents known to cause methemoglobinemia.</p>
</sec>
<sec id="section3-0194599811421124">
<title>Author Contributions</title>
<p><bold>Chad Whited</bold>, study conception, data gathering, analysis, manuscript writing, final approval; <bold>Seth M. Cohen</bold>, study conception, data gathering, analysis, manuscript revision, final approval.</p>
</sec>
<sec id="section4-0194599811421124">
<title>Disclosures</title>
<p><bold>Competing interests:</bold> None.</p>
<p><bold>Sponsorships:</bold> None.</p>
<p><bold>Funding source:</bold> None.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="presented-at">
<p>No sponsorships or competing interests have been disclosed for this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0194599811421124">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Guay</surname><given-names>J</given-names></name>
</person-group>. <article-title>Methemoglobinemia related to local anesthetics: a summary of 242 episodes</article-title>. <source>Anesth Analg</source>. <year>2009</year>;<volume>108</volume>:<fpage>837</fpage>-<lpage>845</lpage>.</citation>
</ref>
<ref id="bibr2-0194599811421124">
<label>2.</label>
<citation citation-type="gov">
<collab>VHA Pharmacy Benefits Management Strategic Healthcare Group and the Medical Advisory Panel and the National Center for Patient Safety</collab>. <comment>A guidance on the use of topical anesthetics for naso/oropharyngeal and laryngotracheal procedures</comment>. <month>February</month> <year>2006</year>. <comment><ext-link ext-link-type="uri" xlink:href="http://www.pbm.va.gov/Clinical%20Guidance/Criteria%20For%20Use/benzocaine.pdf">http://www.pbm.va.gov/Clinical%20Guidance/Criteria%20For%20Use/benzocaine.pdf</ext-link>.</comment> <access-date>Accessed March 18, 2011</access-date>.</citation>
</ref>
<ref id="bibr3-0194599811421124">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Leder</surname><given-names>SB</given-names></name>
<name><surname>Ross</surname><given-names>DA</given-names></name>
<name><surname>Briskin</surname><given-names>KB</given-names></name>
<name><surname>Sasaki</surname><given-names>CT</given-names></name>
</person-group>. <article-title>A prospective, double-blind, randomized study on the use of a topical anesthetic, vasoconstrictor, and placebo during transnasal flexible fiberoptic endoscopy</article-title>. <source>J Speech Lang Hear Res</source>. <year>1997</year>;<volume>40</volume>:<fpage>1352</fpage>-<lpage>1357</lpage>.</citation>
</ref>
<ref id="bibr4-0194599811421124">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Noorily</surname><given-names>AD</given-names></name>
<name><surname>Otto</surname><given-names>RA</given-names></name>
<name><surname>Noorily</surname><given-names>SH</given-names></name>
</person-group>. <article-title>Intranasal anesthetic effects of lidocaine and tetracaine compared</article-title>. <source>Otolaryngol Head Neck Surg</source>. <year>1995</year>;<volume>113</volume>:<fpage>370</fpage>-<lpage>374</lpage>.</citation>
</ref>
<ref id="bibr5-0194599811421124">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lavergne</surname><given-names>S</given-names></name>
<name><surname>Darmon</surname><given-names>M</given-names></name>
<name><surname>Levy</surname><given-names>V</given-names></name>
<name><surname>Azoulay</surname><given-names>E</given-names></name>
</person-group>. <article-title>Methemoglobinemia and acute hemolysis after tetracaine lozenge use</article-title>. <source>J Crit Care</source>. <year>2006</year>;<volume>21</volume>:<fpage>112</fpage>-<lpage>114</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>